NCT03459859已完成1 期
An Open-Label, Dose Escalation, Phase 1 Study of PEVONEDISTAT, a Novel Inhibitor of the NEDD8-Activating Enzyme (NAE), in Combination With Low Dose Cytarabine (LDAC) in Adult Patients With Acute Myelogenous Leukemia (AML) and Advanced Myelodysplastic Syndromes (MDS)
Justin Watts, MD1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2018年5月21日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Safety Profile of Combination Pevonedistat/LDAC Therapy: Rate of Toxicity in Study Participants
研究概览
简要总结
The investigators hypothesize that the combination of Pevonedistat/Low-Dose Cytarabine (LDAC) therapy will be tolerable, that a recommended phase 2 dose of Pevonedistat in combination with LDAC will be identified, and that the combination therapy will show evidence of clinical activity in adult patients with Relapsed/Refractory Acute Myelogenous Leukemia (AML) and Advanced Myelodysplastic Syndromes (MDS).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •A. Confirmed diagnosis of one of the following:
- •Relapsed/refractory Acute Myelogenous Leukemia (AML) where no alternative life prolonging therapy exists. Treatment naïve patients may also be considered eligible if in the opinion of the investigator, these patients are unlikely to benefit from alternative therapy (eg conventional chemotherapy, hypomethylating agents).
- •Relapsed/refractory Myelodysplasic Syndrome (MDS) following at least two courses of a hypomethylating agent (eg azacitidine or decitabine). Patients intolerant of hypomethylating agents (irrespective of the number of cycles administered) will also be considered eligible. MDS eligibility limited to patients with intermediate, high or very high risk based on IPSS-R.
- •B. Adult male or female patients 18 years of age or older.
- •C. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- •D. Patients must satisfy the following laboratory criteria:
- •Albumin > 2.7 g/dL
- •Total bilirubin ≤ upper limit of normal (ULN) except in patients with Gilbert's syndrome. Patients with Gilbert's syndrome may enroll if direct bilirubin ≤1.5 x ULN of the direct bilirubin
- •Alanine transaminase (ALT) and Aspartate transaminase (AST) must be ≤ 2.5 × ULN
- •Creatinine 1.5 x ULN or calculated creatinine clearance > 50ml/min
- •Hemoglobin > 8 g/dL (prior red blood cell (RBC) transfusion allowed). Patients may be transfused to achieve this value. Elevated indirect bilirubin due to post-transfusion hemolysis is allowed.
- •White blood cell (WBC) count < 50,000/µL before administration of PEVONEDISTAT on Cycle 1 Day
- •Note: Hydroxyurea may be used to control the level of circulating leukemic blast cell counts to not lower than 10,000/µL during the study.
- •E. Suitable venous access to allow for all study related blood sampling (safety and research).
- •F. Estimated life expectancy, in the judgment of the Investigator, which will permit receipt of at least 6 weeks of treatment.
- •G. Voluntary written consent must be given before performance of any study related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
- •H. Female patients who:
- •Are postmenopausal (see Appendix for definition) for at least 1 year before the screening visit, OR
- •Are surgically sterile, OR
- •If they are of childbearing potential:
- •Agree to practice 1 highly effective method and 1 additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through 4 months after the last dose of study drug (female and male condoms should not be used together), OR
- •Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception).
- •I. Male patients, even if surgically sterilized (ie, status postvasectomy), who:
- •Agree to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug (female and male condoms should not be used together), OR
- •Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation, symptothermal, postovulation methods for the female partner] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception).
- •J. Able to undergo bone marrow aspiration at screening.
排除标准
- •A. Treatment with clinically significant metabolic enzyme inducers within 14 days before the first dose of the study drug. Strong CYP3A inhibitors and CYP3A inducers are not permitted during the study.
- •B. Therapy with any investigational products, anti-neoplastic therapy, or radiotherapy within 14 days prior to Cycle 1 Day
- •Patients actively receiving hydroxyurea are eligible and may continue to receive hydroxyurea during protocol treatment.
- •C. Candidates for standard and/or potentially curative treatments (a candidate is defined as a patient that is both eligible and willing to have these treatments)
- •D. Major surgery within 14 days before the first dose of any study drug or a scheduled surgery during study period.
- •E. Grade 2 or higher diarrhea as defined by NCI CTCAE Version 4.03 despite optimal anti-diarrheal supportive care within 7 days prior to Cycle1 Day
- •F. Known cardiopulmonary disease defined as one of the following:
- •Uncontrolled high blood pressure (ie, systolic blood pressure > 180 mm Hg, diastolic blood pressure > 95 mm Hg).
- •Cardiomyopathy or history of ischemic heart disease; patients with ischemic heart disease who have had acute coronary syndrome (ACS), MI, and/or revascularization greater than 6 months before screening and who are without cardiac symptoms may enroll;
- •Clinically significant arrhythmia including:,history of polymorphic ventricular fibrillation or torsade de pointes); permanent atrial fibrillation [a fib], defined as a fib for ≥6 months; persistent a fib, defined as sustained afib >7 days and/or requiring cardioversion in the 4 weeks before screening; Grade 3 a fib defined as symptomatic and incompletely controlled medically, or controlled with device (e.g., pacemaker), or ablation. Patients with paroxysmal a fib are permitted to enroll. However, patients with < Grade 3 atrial fibrillation (a fib) for a period of at least 6 months may enroll provided that their rate is controlled on a stable regimen.
- •Implantable cardioverter defibrillator;
- •Congestive heart failure (New York Heart Association (NYHA) Class III or IV; or Class II with a recent decompensation requiring hospitalization or referral to a heart failure clinic within 4 weeks before screening), myocardial infarction and/or revascularization (eg, coronary artery bypass graft, stent) within 6 months of first dose of study drug.
- •Moderate to severe aortic and/or mitral stenosis or other valvulopathy (ongoing);
- •Pulmonary hypertension.
- •Patients with Grade 2 or higher prolonged rate corrected QT (QTc) interval (≥ 481msec), calculated according to institutional guidelines.
- •Left ventricular ejection fraction (LVEF) < 50% as assessed by echocardiogram or radionuclide angiography - LVEF assessment is not required for screening, and will only be done at the investigators discretion if clinically indicated..
- •Known moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosis.
- •G. Active uncontrolled infection or severe infectious disease, such as severe pneumonia, meningitis, or septicemia.
- •H. Known human immunodeficiency virus (HIV) seropositive.
- •I. Known hepatitis B surface antigen seropositive (Note: Patients who have isolated positive hepatitis B core antibody (ie, in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load. Patients who have positive hepatitis C antibody may be included if they have an undetectable hepatitis C viral load.)
- •J. Known or suspected active hepatitis C infections (Patients who are hepatitis C surface antigen-positive are eligible).
- •K. Females of child bearing potential who refuse to either practice 2 effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 30 days after the last dose of study drug.
- •L. Males of child bearing potential who refuse to practice effective barrier contraception during the entire study treatment period and through 4 months after the last dose of study drug. (Includes males surgically sterilized - i.e. status post vasectomy).
- •M. Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before first dose of study drug.
- •N. Female patients who intend to donate eggs (ova) during the course of this study or 4 months after receiving their last dose of study drug(s).
- •O. Male patients who intend to donate sperm during the course of this study or 4 months after receiving their last dose of study drug(s).
- •P. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of study procedures.
- •Q. Symptomatic central nervous system (CNS) involvement.
- •R. Diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection.
- •S. Known hepatic cirrhosis or severe pre-existing hepatic impairment.
- •T. Systemic anti-neoplastic therapy or radiotherapy within 14 days before the first dose of any study drug, except for hydroxyurea.
- •U. Patients with uncontrolled coagulopathy or bleeding disorder.
- •V. Life-threatening illness unrelated to cancer.
研究组 & 干预措施
Pevonedistat 10 LDAC 20
Experimental
Dose Level -1: Pevonedistat 10 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
干预措施: Pevonedistat (Drug)
Pevonedistat 10 LDAC 20
Experimental
Dose Level -1: Pevonedistat 10 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
干预措施: Cytarabine (Drug)
Pevonedistat 15 LDAC 20
Experimental
Dose Level 1 (Starting Dose): Pevonedistat 15 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
干预措施: Pevonedistat (Drug)
Pevonedistat 15 LDAC 20
Experimental
Dose Level 1 (Starting Dose): Pevonedistat 15 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
干预措施: Cytarabine (Drug)
Pevonedistat 20 LDAC 20
Experimental
Dose Level 2: Pevonedistat 20 mg/m2, low dose Cytarabine 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
干预措施: Pevonedistat (Drug)
Pevonedistat 20 LDAC 20
Experimental
Dose Level 2: Pevonedistat 20 mg/m2, low dose Cytarabine 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
干预措施: Cytarabine (Drug)
Pevonedistat 25 LDAC 20
Experimental
Dose Level 3: Pevonedistat 25 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
干预措施: Pevonedistat (Drug)
Pevonedistat 25 LDAC 20
Experimental
Dose Level 3: Pevonedistat 25 mg/m2, low dose Cytarabine (LDAC) 20 mg/m2 for up to 16 cycles of 28 days each, per protocol
干预措施: Cytarabine (Drug)
结局指标
主要结局
Safety Profile of Combination Pevonedistat/LDAC Therapy: Rate of Toxicity in Study Participants
时间窗: From Cycle 1 Day 1 to End of Study, up to 18 months
Rate of toxicity in study participants receiving at least one dose of combination Pevonedistat/LDAC protocol therapy, including determination of dose limiting toxicities (DLTs), serious adverse events (SAEs), and AEs. Toxicity will be assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.03.
Maximum Tolerated Dose (MTD) and Recommended Phase 2 (RP2D) Dose of Pevonedistat in Combination with Low Dose Cytarabine (LDAC)
时间窗: From Cycle 1 Day 1 to End of Study, up to 18 months
Determination of the MTD and RP2D of PEVONEDISTAT administered intravenously in patients with AML and advanced MDS when given in combination with low dose cytarabine (LDAC).
次要结局
- Rate of Efficacy in Study Participants(Up to 17 months)
- Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of Pevonedistat(Cycle 1 Days 1, 2 3, and 5)
- Pharmacokinetics (PK): Time to Cmax (Tmax) of Pevonedistat(Cycle 1 Days 1, 2, 3, and 5)
- Pharmacokinetics (PK): Area Under the Plasma Concentration-Time curve from time 0 to 24 hours post-dose of Pevonedistat (AUC24hr).(Cycle 1 Days 1, 2, 3, and 5)
- Pharmacokinetics (PK): Terminal disposition phase half-life (t1/2) of Plasma Concentration of Pevonedistat(Cycle 1 Days 1, 2, 3, and 5)
- Pharmacodynamics (PD): Induction Levels of CRL substrates(Baseline, Cycle 1 Days 1, 2, and 5; and End of Study, up to 18 months (+/- 10 days))
- Pharmacodynamics (PD): Induction Levels of Pathway Markers(Baseline, Cycle 1 Days 1, 2, and 5; and End of Study, up to 18 months (+/- 10 days))
研究者
Justin Watts, MD
Assistant Professor of Medicine
University of Miami
研究点 (1)
Loading locations...
相似试验
已完成
1 期
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic MalignanciesAdvanced Non-Hematologic MalignanciesNCT01653158Pfizer46
已完成
1 期
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916Multiple MyelomaNCT02064387GlaxoSmithKline79
Unknown
1 期
Phase I Trial to Investigate Cafusertib Hydrochloride Monotherapy in Chinese Patients With Advanced Solid TumoursNeoplasmsNCT02314884Jiangsu Hansoh Pharmaceutical Co., Ltd.40
已完成
1 期
Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal WomenHealthyNCT06315205Rovi Pharmaceuticals Laboratories84
撤回
1 期
Study of Select Combinations in Adults With MyelofibrosisPost-Essential Thrombocythemia MyelofibrosisPost-Polycythemia Vera MyelofibrosisMyelofibrosisPrimary MyelofibrosisPMFNCT04283526Novartis Pharmaceuticals